Yuntian Tang

Yuntian Tang


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2022
Verified
Journal Article
Closed access
QZQiuhuan Zhang
Qiuhuan Zhang
YTYi Tang
Yi Tang
GHGuimei Hu
Guimei Hu
ZYZhuoer Yuan
Zhuoer Yuan
SZShengyue Zhang
Shengyue Zhang
YTYuntian Tang
Yuntian Tang

16 October 2026 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
YTYi Tang
Yi Tang
QZQiuhuan Zhang
Qiuhuan Zhang
XWXuanchao Wen
Xuanchao Wen
RLRongjun Liu
Rongjun Liu
SXShaowei Xie
Shaowei Xie
YTYuntian Tang
Yuntian Tang

1 October 2026 in BMC Endocrine Disorders
Verified
Journal Article
Open access
PDF file
WWWang Weizhi
Wang Weizhi
LMLi Mengyang
Li Mengyang
YTYuntian Tang
Yuntian Tang
To develop and validate a nomogram based on LASSO and multivariable logistic regression for predicting preoperative central lymph node metastasis (CLNM) in

1 August 2026 in Molecular Carcinogenesis
Verified
Journal Article
Open access
ZHZhen Huang
Zhen Huang
ZWZhe Wu
Zhe Wu
GZGuiyue Zhu
Guiyue Zhu
FQFangyu Qiu
Fangyu Qiu
LLLihui Li
Lihui Li
YTYuntian Tang
Yuntian Tang
Neutrophil extracellular traps (NETs) play crucial roles in cancer progression, but their regulatory mechanisms in breast cancer remain poorly understood. We developed a NETs‐related prognostic risk model using TCGA breast cancer data and identified key biomarkers through bioinformatics analysis. AZU1 expression was validated in clinical samples using qRT‐PCR and immunohistochemistry. In vitro experiments investigated AZU1's effects on neutrophil activation and NET formation using recombinant protein treatment, co‐culture assays, and flow cytometry. Mechanistic studies employed phospholipase C (PLC) inhibition and PAD4 knockdown approaches. An orthotopic mouse model validated in vivo findings. Four NETs‐related genes (F2RL2, AZU1, IL33, ELANE) constituted a robust prognostic model with good predictive performance. AZU1 showed significant upregulation in breast cancer tissues and correlated with advanced tumor stages. AZU1 overexpression in breast cancer cells enhanced neutrophil recruitment and NET formation through PLC signaling activation. Recombinant AZU1 dose‐dependently activated neutrophils, promoted NET formation, and enhanced cancer cell invasion via epithelial‐mesenchymal transition induction. PLC inhibition and PAD4 knockdown effectively blocked AZU1‐induced neutrophil activation. In vivo experiments confirmed that AZU1 overexpression accelerated tumor growth and metastasis, while PAD4 inhibition reversed these effects. AZU1 promotes breast cancer progression through PAD4‐dependent NET formation, representing a potential therapeutic target for breast cancer treatment.

4 July 2026 in Human Cell
Verified
Journal Article
Closed access
YTYi Tang
Yi Tang
ZTZhenyong Tang
Zhenyong Tang
RLRongjun Liu
Rongjun Liu
SXShaowei Xie
Shaowei Xie
BCBin Chen
Bin Chen
YTYuntian Tang
Yuntian Tang